Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a ...

Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

in as a second-line or later therapy for diffuse large B-cell lymphoma (DLBCL), another blood cancer treated with CAR-T therapy. Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a ...

The incidence of non-Hodgkin’s lymphoma (NHL) is increasing among ... characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients ...

Primary central nervous system lymphoma (PCNSL) is a rare disease that is managed differently from other primary brain tumors and other types of systemic lymphomas. The use of high-dose ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...